Difference between revisions of "Team:SYSU-MEDICINE"

Line 529: Line 529:
 
         </div>
 
         </div>
 
         <div class="item">
 
         <div class="item">
−
             <img style='height: auto ;width: 100%' src="https://static.igem.org/mediawiki/2016/c/c4/T--SYSU-MEDICINE--home-1.png" alt="...">
+
             <img style='height: auto ;width: 100%' src="https://static.igem.org/mediawiki/2016/f/f4/T--SYSU-MEDICINE--home-1.jpeg" alt="...">
 
             <div class="carousel-caption">
 
             <div class="carousel-caption">
 
                 <h1 style="font-size:80px">SYSU-MEDICINE</h1>
 
                 <h1 style="font-size:80px">SYSU-MEDICINE</h1>
Line 537: Line 537:
 
         </div>
 
         </div>
 
         <div class="item">
 
         <div class="item">
−
             <img style='height: auto ;width: 100%' src="https://static.igem.org/mediawiki/2016/5/55/T--SYSU-MEDICINE--home-2.jpg" alt="...">
+
             <img style='height: auto ;width: 100%' src="https://static.igem.org/mediawiki/2016/4/45/T--SYSU-MEDICINE--home-2.jpeg" alt="...">
 
             <div class="carousel-caption">
 
             <div class="carousel-caption">
 
                 <h1 style="font-size:80px">SYSU-MEDICINE</h1>
 
                 <h1 style="font-size:80px">SYSU-MEDICINE</h1>

Revision as of 21:19, 19 October 2016

MSCavalry

-----MSCs of
next generation

Inflammatory diseases are an increasing cause of disability and even fatality. Currently, apart from common treatments, MSCs therapy is a promising candidate for curing inflammatory diseases. However, intravascular injected MSCs are criticized for its low homing efficiency and ambiguous distribution in human body.

This year, MSCavalry: MSCs of next generation is coming. SYSU-MEDICINE decide to engineer a set of MSCs (homo sapiens) with higher accuracy and we hope that our project can pave the way for future MSCs clinical application.